**supplementary Table S2 Accompanying symptoms at 48 weeks (NUH01FMF, NUH02FMF, FAS)**

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | Placebo (n=11) | Tocilizumab (n= 12) | Total (n=23) |
| Accompanying symptoms (/week) |  |  | 　 |
|  any | 0.0901 (0.1836) | 0.1114 (0.1746) | 0.1003 (0.1756) |
|  abnominal pain | 0.0350 (0.0710) | 0.0189 (0.0270) | 0.0273 (0.0540) |
|  chest pain | 0.0326 (0.0900) | 0.013 (0.0269) | 0.0224 (0.0671) |
|  arthritis | 0.0104 (0.0258) | 0.0566 (0.1544) | 0.0325 (0.1083) |
|  headache | 0.0069 (0.0240) | 0.0151 (0.0280) | 0.0108 (0.0257) |

(SD)